A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase ...

Early-stage non-small cell lung cancer (NSCLC) offers a better prognosis than advanced stages. Staging helps inform treatment by describing your cancer's size, lymph node involvement, and metastasis.

Doctors typically divide small cell lung cancer (SCLC) into limited or extensive stages, depending on whether the cancer is in one lung, both lungs, or has spread to distant areas. Staging for small ...

On the heels of two FDA approvals in lung cancer treatments, what innovations are next? As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung ...

People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest ...

A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...